Allergan Aesthetics Continues Partnership with Girls Inc to Empower Confidence in High School-Aged Girls Interested in STEM pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Allergan Aesthetics to Acquire Soliton, Expanding Body Contouring Portfolio
Allergan Aesthetics, an ABBVie company and Soliton today announced a definitive agreement under which Allergan Aesthetics will acquire Soliton and RESONIC TM its Rapid Acoustic Pulse device which recently received U.S. Food and Drug Administration 510 clearance and is a non-invasive treatment for the short-term improvement in the appearance of cellulite. The acquisition of Soliton expands and complements Allergan …
– Allergan Aesthetics, an ABBVie company (NYSE: ABBV) and Soliton (NASDAQ: SOLY) today announced a definitive agreement under which Allergan Aesthetics will acquire Soliton and RESONIC TM its Rapid Acoustic Pulse device which recently received U.S. Food and Drug Administration (FDA) 510(k) clearance and is a non-invasive treatment for the short-term improvement in the appearance of cellulite. The acquisition of Soliton expands and complements Allergan Aesthetics’ Body Contouring treatment
May 10, 2021 12:05pm The deal is built around Soliton’s Resonic cellulite and tattoo removal device, which uses rapid pulses of acoustic shockwaves to help fade unwanted ink and break apart undesired fat deposits for short-term improvements in its dimpled appearance. (Getty Images)
After launching the commercial rollout of its first FDA-cleared device just last week, Soliton will have little time to rest on its laurels it s been targeted by AbbVie’s Allergan Aesthetics division for a $550 million acquisition to help expand the Big Pharma’s body contouring portfolio.
The deal is built around Soliton’s Resonic cellulite and tattoo removal device, which uses rapid pulses of acoustic shockwaves to help fade unwanted ink and break apart undesired fat deposits for short-term improvements in its dimpled appearance.
Allergan Aesthetics Enters Into Option to Acquire Cypris Medical Agreement Includes Development of Xact Device, a Minimally-Invasive Alternative Option for Performing Face and Neck Lifts Allergan Aesthetics & Cypris to Partner on Clinical Trial
News provided by
Share this article
Share this article
IRVINE, Calif., Jan. 12, 2021 /PRNewswire/ Today Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that it has entered into a warrant agreement with Cypris Medical, a privately held, medical device company based in Chicago. Following the completion of a clinical trial to be initiated in 2021, Allergan Aesthetics will have the right to exercise an option to acquire Cypris Medical, including the company s Xact device. The planned clinical trial will evaluate the safety and effectiveness of Xact in treating midface descent as well as for neck lifts.